NEW YORK, August 23, 2016 /PRNewswire/ --
Biotechnology harnesses cellular and biomolecular processes to develop technologies and products, which include food technology, genetic research, healthcare, and environmental technology. Equities under assessment on Stock-Callers.com today are: Halozyme Therapeutics Inc. (NASDAQ: HALO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Chimerix Inc. (NASDAQ: CMRX). These stocks research reports can be downloaded now by simply registering for free at:
San Diego, California headquartered Halozyme Therapeutics Inc.'s stock finished Monday's session 3.21% higher at $10.30 with a total volume of 841,534 shares traded. The Company's shares have advanced 11.47% in the past month and 10.52% over the previous three months. The stock is trading above its 50-day moving average by 10.72%. Furthermore, shares of Halozyme Therapeutics, which researches, develops, and commercializes human enzymes, have a Relative Strength Index (RSI) of 56.45.
On August 9th, 2016, Halozyme Therapeutics reported that revenue for Q2 2016 was $33.3 million, compared to $43.4 million for Q2 2015. Revenue in the prior year period included $23 million for the initiation of the company's partnership with AbbVie. Excluding the $23 million payment, revenue grew 64% on y-o-y basis. The company's net loss for Q2 2016 was $26.9 million, or $0.21 per share, compared to net income in Q2 2015 of $3 million, or $0.02 per share. Your complete research report on HALO can be retrieved for free at:
On Monday, shares in New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc. ended the session at $9.29, jumping 4.97%. The stock recorded a trading volume of 1.69 million shares, which was above its three months average volume of 1.30 million shares. The Company's shares have gained 8.02% in the last one month and 9.42% in the previous three months. The stock is trading 7.67% above its 50-day moving average and 9.57% above its 200-day moving average. Moreover, shares of Achillion Pharmaceuticals, which discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the US and internationally, have an RSI of 61.41.
On August 4th, 2016, Achillion Pharma reported a net loss of $18.5 million for the three months ended June 30th, 2016, compared to a net loss of $29.0 million during the same period of 2015. During the three months ended June 30th, 2016 Achillion did not recognize any revenue compared to revenue of $711,000 under an agreement with Janssen that was recognized in the same period of 2015. ACHN free report is just a click away at:
Cambridge, Massachusetts headquartered Aegerion Pharmaceuticals Inc.'s stock ended yesterday's session 1.96% higher at $1.56 with a total volume of 34,372 shares traded. The Company's shares have advanced 6.85% in the past month. The stock is trading 2.04% above its 50-day moving average. Additionally, shares of Aegerion Pharmaceuticals, which develops and commercializes therapies for patients with debilitating rare diseases in the US, have an RSI of 51.35.
On August 9th, 2016, Aegerion Pharmaceuticals reported that total net product sales for Q2 ended June 30, 2016 were $44.5 million compared to $64.2 million in Q2 2015. The company's non-GAAP net loss for Q2 ended June 30th, 2016, was $21.4 million, or $0.72 basic loss per share, compared to non-GAAP net income of $6.2 million, or $0.22 basic earnings per share, for the same period in 2015. Sign up for your complimentary research report on AEGR at:
At the close on Monday, shares in Durham, North Carolina headquartered Chimerix Inc. recorded a trading volume of 933,055 shares, which was higher than their three months average volume of 658,450 shares. The stock edged 9.28% higher at $4.71. The Company's shares have surged 14.32% in the last one month. The stock is trading above its 50-day moving average by 16.48%. Furthermore, shares of Chimerix, which discovers, develops, and commercializes oral antivirals in the areas of unmet medical needs in the US, have an RSI of 62.97.
On August 8th, 2016, Chimerix reported that net loss decreased to $18.1 million, or $0.39 per basic and diluted share, for Q2 2016 compared to a net loss of $24.8 million, or $0.59 per basic and diluted share, during the same period in 2015. The company's revenues for Q2 2016 decreased to $1.8 million compared to $4.1 million for the same period in 2015.
On August 09th, 2016, research firm FBR Capital reiterated its 'Market Perform' rating on the Company's stock with a decrease of the target price from $9 a share to $8 a share. Register for free on Stock-Callers.com and download the latest research report on CMRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA